Kieron Dunleavy, MD, from the National Cancer Institute, Bethesda, MD, discusses BTK inhibition in primary CNS lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. Following the success of studies investigating the use of ibrutinib in activated B-cell-like (ABC) diffuse large B-cell lymphoma, the drug is being tested in primary CNS lymphoma. There are some similarities between ABC lymphoma and primary CNS lymphoma, and certain mutations, such as CD79B and MYD88, indicate that BTK inhibition may be effective. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.